Voyager Therapeutics Revenue, Profits - VYGR Quarterly Income Statement

Add to My Stocks
$22.9 $0.4 (1.78%) VYGR stock closing price Jun 22, 2018 (Closing)

Stock analysis based on fundamentals means looking at financial statements in addition to the Voyager Therapeutics stock price. The income statement gives the investor an understanding of the topline or revenue and bottomline or profit numbers of the company and helps investors evaluate if a company has been growing or not. The income statement for VYGR which shows a YOY revenue decline of 0 is specific to a period of time. Investors typically check YoY or QoQ revenue growth. The Voyager Therapeutics profit and loss statement for 2018 Q1 shows a net profit of $-19.93M. Profits for last year was $-11.77M. Apart from this an investor should also check Voyager Therapeutics assets and Voyager Therapeutics free cash flow.

View and download details of revenue and profits for Voyager Therapeutics for latest & last 40 quarters.
show more
View Previous Quarters
View Next Quarters
Fiscal year is Jan - Dec2018 Q12017 Q42017 Q32017 Q22017 Q12016 Q42016 Q32016 Q22016 Q12015 Q4
Voyager Therapeutics Revenues or Net Sales
Cost Of Goods Sold (COGS)----------
Voyager Therapeutics Gross Profit
Research & Development Expense14.85M13.33M19.56M15.3M14.07M12.73M10.3M10.48M8.73M9.22M
Selling General & Admin Expense7.18M5.37M4.94M4.51M4.91M3.49M3.37M2.85M3.56M3.16M
Income Before Depreciation Depletion Amortization-21.09M-12.36M-23.35M-18.63M-17.52M-13.85M-10.37M-9.61M-7.46M-7.46M
Depreciation Depletion Amortization----------
Non Operating Income----0.04M--0.47M1.07M---
Interest Expense----------
Voyager Therapeutics Pretax Income
Provision for Income Taxes-0.18M----0.22M--0.3M---
Investment Gains Losses----------
Other Income----------
Income Before Extraordinaries & Disc Operations-19.93M-11.77M-23.35M-18.88M-16.65M-14.67M-9M-9.34M-7.19M-7.28M
Extraordinary Items & Discontinued Operations----------
Voyager Therapeutics Profit/ Loss (Net Income)
Average Shares used to compute Diluted EPS31.76M29.28M26.17M25.95M25.79M25.53M25.37M25.23M24.79M13.16M
Average Shares used to compute Basic EPS31.76M29.28M26.17M25.95M25.79M25.53M25.37M25.23M24.79M13.16M
Income Before Nonrecurring Items-19.93M-11.77M-23.35M-18.88M-16.65M-14.67M-9M-9.34M-7.19M-7.28M
Income from Nonrecurring Items----------
Voyager Therapeutics Earnings Per Share Basic Net
Voyager Therapeutics Earnings Per Share Diluted Net
EPS Diluted Before Nonrecurring Items-0.63-0.40-0.89-0.73-0.65-0.57-0.35-0.37-0.29-0.67
Preferred Dividends Acc Pd----------
Dividends Common0.000.00--------
Dividend Per Share Common0.
All figures in USD. M: Millions of USD, B: Billions of USD.
View Previous Quarters
View Next Quarters

Voyager Therapeutics stock analysis involves checking at least a few of the important things like:

  • Revenue: The money received by selling of goods or services comes under this line item. A QoQ growth - See: Voyager Therapeutics revenue chart, implies that the company is growing. It has not been the case with Voyager Therapeutics. One must look at stocks with increasing revenues, and stay away from stocks whose revenues or sales are declining.
  • Bottom line: This refers to the last line in a profit and loss statement and denotes the net profit or loss for a particular period. The figure currently stands at $-19.93M for Voyager Therapeutics for 2018 Q1. This figure is arrived at after deducting all operating expenses, interest, and taxes from revenue.

The income statement is also called statement of revenue and expense. The VYGR financials along with Voyager Therapeutics historical stock prices provide a lot of details about the firm.

Voyager Therapeutics Income Statement - Key Financial Ratios

PS Ratio (price sales ratio)
Dividend Yield